Tripos Discovery Research Enters Agreement with CombinatoRx to Optimize Novel Compounds
News Aug 29, 2007
Tripos Discovery Research Limited (TDR), a wholly owned subsidiary of Commonwealth Biotechnologies, Inc. has announced that it has entered into a service agreement with CombinatoRx, Incorporated (CombinatoRx).
Using its combination “High Throughput Screening” technology, cHTS™, CombinatoRx has identified synergistic combinations with utility in key indications which TDR will optimize utilizing its expertise in computational and medicinal chemistry and partner ADME services.
Dr. Mark Warne, Managing Director of TDR, stated, “We are delighted to be entering into this new and exciting agreement with CombinatoRx. Following TDR’s recent acquisition by CBI, this agreement serves as further confirmation that we remain focused on providing integrated drug discovery services to the pharmaceutical and biotech community, working closely with our clients throughout the drug discovery process.”
Novel Chemistry Technique Simplifies Late-Stage Modification of Drug CompoundsNews
Chemists at The Scripps Research Institute (TSRI) have invented a technique that overcomes a long-standing problem in organic chemistry and should streamline the process of discovery and development for many new drugs.READ MORE
AIDS Vaccine Design: New Data Offers Important InsightNews
New data published in Immunity further illuminate how some human beings generate powerful, HIV-blocking antibodies. The results offer important insight into a potential AIDS vaccine design.READ MORE